Drug development for controlling Ebola epidemic-A race against time

Drug Discoveries & Therapeutics

Volumn 8, Issue 5, 2011, Pages 229-231

  Gao, Jianjun ^a   Yin, Lin ^b  

^a QINGDAO UNIVERSITY   (China)

^b Hitachi Beijing Tech Information System Co Ltd   (China)

Author keywords

Africa; jk 05; TKM Ebola; vaccine; ZMapp

Indexed keywords

EBOLA VACCINE;

EPIDEMIC; HEMORRHAGIC FEVER, EBOLA; HUMAN; IMMUNOLOGY;

DISEASE OUTBREAKS; EBOLA VACCINES; EPIDEMICS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84930246938     PISSN: 18817831     EISSN: 1881784X     Source Type: Journal    
DOI: 10.5582/ddt.2014.01040     Document Type: Article

References (16)

1. WHO: Ebola Response Roadmap update, 17 October 2014. http: //www.who.int/csr/disease/ebola/zh/ (accessed October 21, 2014).
2. Team WHOER. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med. 2014; 371: 1481-1495.
3. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014; 514: 47-53.
4. Olinger GG, Jr., Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012; 109: 18030-18035.
5. Pettitt J, Zeitlin L, Kim do H, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013; 5: 199-113.
6. McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ. 2014; 349: g5488.
7. McCarthy M. FDA allows second experimental drug to be tested in Ebola patients. BMJ. 2014; 349: g5103.
8. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I. Postexposure protection of nonhuman primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010; 375: 1896-1905.
9. News. The first anti-Ebola drug is approved in China. Information China (E-Healthcare). 2014; 9: 12.
10. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009; 82: 95-102.
11. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Postexposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014; 104: 153-155.
12. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014; 105: 17-21.
13. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014; 508: 402-405.
14. Kanapathipillai R, Restrepo AM, Fast P, Wood D, Dye C, Kieny MP, Moorthy V. Ebola Vaccine-An Urgent International Priority. N Engl J Med. 2014. DOI: 10.1056/ NEJMp1412166
15. Butler D. Ebola drug trials set to begin amid crisis. Nature. 2014; 513: 13-14.
16. ClinicalTrials.gov. http: //www.clinicaltrials.gov/ct2/results ?term=Curcumin++alzheimer&Search=Search (accessed October 21, 2014).